[go: up one dir, main page]

WO2009055074A8 - Erbb2 binding proteins and use thereof - Google Patents

Erbb2 binding proteins and use thereof Download PDF

Info

Publication number
WO2009055074A8
WO2009055074A8 PCT/US2008/012212 US2008012212W WO2009055074A8 WO 2009055074 A8 WO2009055074 A8 WO 2009055074A8 US 2008012212 W US2008012212 W US 2008012212W WO 2009055074 A8 WO2009055074 A8 WO 2009055074A8
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
erbb2 binding
erbb2
human
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/012212
Other languages
French (fr)
Other versions
WO2009055074A2 (en
WO2009055074A3 (en
Inventor
Davinder Gill
Fionnuala Mcaleese
Maximillian Follettie
Laird Bloom
Peter A Thompson
Peter R Baum
Paul A Algate
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Trubion Pharmaceuticals Inc
Original Assignee
Wyeth LLC
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/006905 external-priority patent/WO2008150485A2/en
Application filed by Wyeth LLC, Trubion Pharmaceuticals Inc filed Critical Wyeth LLC
Publication of WO2009055074A2 publication Critical patent/WO2009055074A2/en
Publication of WO2009055074A8 publication Critical patent/WO2009055074A8/en
Publication of WO2009055074A3 publication Critical patent/WO2009055074A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
PCT/US2008/012212 2007-10-25 2008-10-27 Erbb2 binding proteins and use thereof Ceased WO2009055074A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51107P 2007-10-25 2007-10-25
US61/000,511 2007-10-25
US6243308P 2008-01-24 2008-01-24
US61/062,433 2008-01-24
USPCT/US2008/006905 2008-05-29
PCT/US2008/006905 WO2008150485A2 (en) 2007-05-29 2008-05-29 Erbb2 binding proteins and use thereof

Publications (3)

Publication Number Publication Date
WO2009055074A2 WO2009055074A2 (en) 2009-04-30
WO2009055074A8 true WO2009055074A8 (en) 2009-08-06
WO2009055074A3 WO2009055074A3 (en) 2009-09-11

Family

ID=40512895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012212 Ceased WO2009055074A2 (en) 2007-10-25 2008-10-27 Erbb2 binding proteins and use thereof

Country Status (1)

Country Link
WO (1) WO2009055074A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096401A (en) * 2017-06-20 2018-12-28 苏州纳洛迈生物科技有限公司 Anti- Her2 nano antibody and its coded sequence and purposes

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2769729T1 (en) 2007-09-04 2019-06-28 Compugen Ltd. Polypeptidine and polynucleotides and their uses as the target of medicines for medicinal products and biological medicines
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
ES2733921T3 (en) * 2010-05-27 2019-12-03 Genmab As Monoclonal antibodies against HER2
CN103153339B (en) 2010-05-27 2021-05-04 根马布股份公司 Monoclonal antibodies against HER2 epitope
JP2014514314A (en) 2011-04-20 2014-06-19 ゲンマブ エー／エス Bispecific antibodies against HER2 and CD3
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2756093A4 (en) 2012-02-01 2015-07-01 Compugen Ltd C10RF32 ANTIBODIES AND USES THEREOF FOR TREATING CANCER
HUE053097T2 (en) 2015-03-31 2021-06-28 Medimmune Ltd Novel IL33, mutated forms of IL33, antibodies, assays and methods for their use
CN106699888B (en) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 PD-1 antibody and preparation method and application thereof
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
CN110305217B (en) * 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 Bispecific antibodies and their applications
WO2025064498A1 (en) * 2023-09-18 2025-03-27 The Trustees Of Columbia University In The City Of New York Affinity-modulated anti-cd45 x pd-1 and anti-cd43 x pd-1 bispecific antibodies to treat cancer and autoimmunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096401A (en) * 2017-06-20 2018-12-28 苏州纳洛迈生物科技有限公司 Anti- Her2 nano antibody and its coded sequence and purposes
CN109096401B (en) * 2017-06-20 2021-07-27 和迈生物科技有限公司 Anti-Her2 nanobodies and their coding sequences and uses

Also Published As

Publication number Publication date
WO2009055074A2 (en) 2009-04-30
WO2009055074A3 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2009055074A3 (en) Erbb2 binding proteins and use thereof
IL281876A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
HUS1800021I1 (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2009070243A3 (en) Wise binding antibodies and epitopes
IL197831A (en) Human antibodies that bind cxcr4, compositions comprising the same and uses thereof
EP2097534A4 (en) Human antibodies that bind cd70 and uses thereof
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
MA32190B1 (en) Antibodies to angiopoietin 1 and angiopoietin 2 and their use
IL204615A0 (en) Human antibodies that bind mesothelin, and uses thereof
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2012092539A3 (en) Antibodies to dll4 and uses thereof
HK1131191A (en) Human antibodies that bind cd70 and uses thereof
AU2012261508A1 (en) Wise binding antibodies and epitopes
HK1133894A (en) Multispecific epitope binding proteins and uses thereof
HK1136850A (en) Human antibodies that bind cd19 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842686

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08842686

Country of ref document: EP

Kind code of ref document: A2